Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 3
2015 5
2016 1
2017 2
2018 2
2019 1
2020 2
2022 3
2023 4
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
Döhner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, Lübbert M, Kühn MWM, Schroeder T, Salwender H, Götze K, Westermann J, Fransecky L, Mayer K, Hertenstein B, Ringhoffer M, Tischler HJ, Machherndl-Spandl S, Schrade A, Paschka P, Gaidzik VI, Theis F, Thol F, Heuser M, Schlenk RF, Bullinger L, Saadati M, Benner A, Larson R, Stone R, Döhner K, Ganser A. Döhner H, et al. Among authors: saadati m. Blood Adv. 2022 Sep 27;6(18):5345-5355. doi: 10.1182/bloodadvances.2022007223. Blood Adv. 2022. PMID: 35486475 Free PMC article. Clinical Trial.
Marginal variable screening for survival endpoints.
Edelmann D, Hummel M, Hielscher T, Saadati M, Benner A. Edelmann D, et al. Among authors: saadati m. Biom J. 2020 May;62(3):610-626. doi: 10.1002/bimj.201800269. Epub 2019 Aug 26. Biom J. 2020. PMID: 31448463 Review.
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati M, Benner A, Schlenk RF, Döhner K, Ganser A; German–Austrian AML Study Group. Döhner H, et al. Among authors: saadati m. Lancet Haematol. 2023 Jul;10(7):e495-e509. doi: 10.1016/S2352-3026(23)00089-3. Epub 2023 May 12. Lancet Haematol. 2023. PMID: 37187198 Clinical Trial.
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz GJ, Bullinger L, Lutsik P, Riedel A, Plass C, Jahn N, Walter C, Holzmann K, Hao Y, Naim S, Schreck N, Krzykalla J, Benner A, Keer HN, Azab M, Döhner K, Döhner H. Jahn E, et al. Among authors: saadati m. Leukemia. 2023 Nov;37(11):2187-2196. doi: 10.1038/s41375-023-01999-6. Epub 2023 Aug 17. Leukemia. 2023. PMID: 37591941 Free PMC article.
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn N, Jahn E, Saadati M, Bullinger L, Larson RA, Ottone T, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Ehninger G, Heuser M, Ganser A, Pallaud C, Gathmann I, Krzykalla J, Benner A, Bloomfield CD, Thiede C, Stone RM, Döhner H, Döhner K. Jahn N, et al. Among authors: saadati m. Leukemia. 2022 Sep;36(9):2218-2227. doi: 10.1038/s41375-022-01650-w. Epub 2022 Aug 3. Leukemia. 2022. PMID: 35922444 Free PMC article. Clinical Trial.
Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Shahswar R, Beutel G, Gabdoulline R, Schwarzer A, Kloos A, Koenecke C, Stadler M, Gohring G, Behrens YL, Li Z, Dallmann LK, Klement P, Albert C, Wichmann M, Alwie Y, Benner A, Saadati M, Ganser A, Thol F, Heuser M. Shahswar R, et al. Among authors: saadati m. Haematologica. 2024 Jan 1;109(1):72-83. doi: 10.3324/haematol.2023.282912. Haematologica. 2024. PMID: 37470150 Free PMC article.
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
Appelbaum JS, Wei AH, Mandrekar SJ, Tiong IS, Chua CC, Teh TC, Fong CY, Ting SB, Weber D, Benner A, Hill H, Saadati M, Yin J, Stone RM, Garcia-Manero G, Erba HP, Uy GL, Marcucci G, Larson RA, Thomas A, Freeman SD, Almuina NM, Döhner K, Thomas I, Russel NH, Döhner H, Othus M, Estey EH, Walter RB. Appelbaum JS, et al. Among authors: saadati m. Leukemia. 2024 Feb;38(2):389-392. doi: 10.1038/s41375-024-02143-8. Epub 2024 Jan 23. Leukemia. 2024. PMID: 38263433 No abstract available.
Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
Hütter-Krönke ML, Neagoie A, Blau IW, Wais V, Vuong L, Gantner A, Ahn J, Penack O, Schnell J, Nogai KA, Eberspächer B, Saadati M, Benner A, Bullinger L, Döhner H, Bunjes D, Sala E. Hütter-Krönke ML, et al. Among authors: saadati m. Front Immunol. 2023 May 3;14:1174289. doi: 10.3389/fimmu.2023.1174289. eCollection 2023. Front Immunol. 2023. PMID: 37207199 Free PMC article.
25 results